Natera’s Foresight Diagnostics Acquisition Named Deal of the Year by CBSA
Natera/LinkedIn

Natera’s Foresight Diagnostics Acquisition Named Deal of the Year by CBSA

Natera shared on LinkedIn:

“Natera’s 2025 acquisition of Foresight Diagnostics was recently recognized as Deal of the Year by the Colorado BioScience Association (CBSA).

Jake Chabon, SVP, and General Manager, Hematology Franchise at Natera, accepted the award on the company’s behalf during CBSA’s 23rd Annual Awards Celebration in Denver, Colorado. The event celebrated people and organizations contributing to a life sciences community focused on improving lives around the world. Thank you, CBSA, for this honor and congratulations to the team.”

About Natera

Natera is a global diagnostics company headquartered in Austin, Texas, founded in 2004. It develops genetic testing and screening solutions, with a focus on oncology, women’s health and organ health.

In oncology, the company is best known for Signatera, a personalized blood test that detects molecular residual disease and helps monitor the risk of cancer recurrence. Its other tests include Panorama, used for prenatal screening, and Prospera, which helps assess the risk of organ transplant rejection.

Natera also works with healthcare professionals and research institutions to advance diagnostic technologies and improve how diseases are detected and monitored.

You may also be interested in: Natera Wins Best in Class Award at HLTH 2026 for Cancer Detection

Natera